Literature DB >> 12750461

Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta.

Minako Hoshi1, Michio Sato, Shinichiro Matsumoto, Akihiko Noguchi, Kaori Yasutake, Natsuko Yoshida, Kazuki Sato.   

Abstract

beta-Amyloid (Abeta) acquires toxicity by self-aggregation. To identify and characterize the toxic form(s) of Abeta aggregates, we examined in vitro aggregation conditions by using large quantities of homogenous, chemically synthesized Abeta1-40 peptide. We found that slow rotation of Abeta1-40 solution reproducibly gave self-aggregated Abeta1-40 containing a stable and highly toxic moiety. Examination of the aggregates purified by glycerol-gradient centrifugation by atomic force microscopy and transmission electron microscopy revealed that the toxic moiety is a perfect sphere, which we call amylospheroid (ASPD). Other Abeta1-40 aggregates, including fibrils, were nontoxic. Correlation studies between toxicity and sphere size indicate that 10- to 15-nm ASPD was highly toxic, whereas ASPD <10 nm was nontoxic. A positive correlation between the toxicity and ASPD >10 nm also appeared to exist when Abeta1-42 formed ASPD by slow rotation. However, Abeta1-42-ASPD formed more rapidly, killed neurons at lower concentrations, and showed approximately 100-fold-higher toxicity than Abeta1-40-ASPD. The toxic ASPD was associated with SDS-resistant oligomeric bands in immunoblotting, which were absent in nontoxic ASPD. Because the formation of ASPD was not disturbed by pentapeptides that break beta-sheet interactions, Abeta may form ASPD through a pathway that is at least partly distinct from that of fibril formation. Inhibition experiments with lithium suggest the involvement of tau protein kinase I/glycogen synthase kinase-3beta in the early stages of ASPD-induced neurodegeneration. Here we describe the identification and characterization of ASPD and discuss its possible role in the neurodegeneration in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12750461      PMCID: PMC164453          DOI: 10.1073/pnas.1237107100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide.

Authors:  T H Huang; D S Yang; N P Plaskos; S Go; C M Yip; P E Fraser; A Chakrabartty
Journal:  J Mol Biol       Date:  2000-03-17       Impact factor: 5.469

2.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 3.  Anti-bipolar therapy: mechanism of action of lithium.

Authors:  R S Jope
Journal:  Mol Psychiatry       Date:  1999-03       Impact factor: 15.992

4.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

5.  Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration.

Authors:  G Alvarez; J R Muñoz-Montaño; J Satrústegui; J Avila; E Bogónez; J Díaz-Nido
Journal:  FEBS Lett       Date:  1999-06-25       Impact factor: 4.124

6.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Authors:  L F Lue; Y M Kuo; A E Roher; L Brachova; Y Shen; L Sue; T Beach; J H Kurth; R E Rydel; J Rogers
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

7.  Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.

Authors:  D M Hartley; D M Walsh; C P Ye; T Diehl; S Vasquez; P M Vassilev; D B Teplow; D J Selkoe
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

8.  Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy.

Authors:  C Soto; E M Sigurdsson; L Morelli; R A Kumar; E M Castaño; B Frangione
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

9.  Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases.

Authors:  Monica Bucciantini; Elisa Giannoni; Fabrizio Chiti; Fabiana Baroni; Lucia Formigli; Jesús Zurdo; Niccolò Taddei; Giampietro Ramponi; Christopher M Dobson; Massimo Stefani
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

10.  Improvements in epoxy resin embedding methods.

Authors:  J H LUFT
Journal:  J Biophys Biochem Cytol       Date:  1961-02
View more
  139 in total

1.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

2.  Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity.

Authors:  Ali Reza A Ladiwala; Jeffrey Litt; Ravi S Kane; Darryl S Aucoin; Steven O Smith; Swarnim Ranjan; Judianne Davis; William E Van Nostrand; Peter M Tessier
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

3.  Probing the efficacy of peptide-based inhibitors against acid- and zinc-promoted oligomerization of amyloid-β peptide via single-oligomer spectroscopy.

Authors:  Lyndsey R Powell; Kyle D Dukes; Robin K Lammi
Journal:  Biophys Chem       Date:  2011-09-08       Impact factor: 2.352

4.  Polymorphic C-terminal beta-sheet interactions determine the formation of fibril or amyloid beta-derived diffusible ligand-like globulomer for the Alzheimer Abeta42 dodecamer.

Authors:  Buyong Ma; Ruth Nussinov
Journal:  J Biol Chem       Date:  2010-09-16       Impact factor: 5.157

5.  Measurement of the attachment and assembly of small amyloid-β oligomers on live cell membranes at physiological concentrations using single-molecule tools.

Authors:  Suman Nag; Jiji Chen; J Irudayaraj; S Maiti
Journal:  Biophys J       Date:  2010-09-22       Impact factor: 4.033

6.  Studying polyglutamine aggregation in Caenorhabditis elegans using an analytical ultracentrifuge equipped with fluorescence detection.

Authors:  Bashkim Kokona; Carrie A May; Nicole R Cunningham; Lynn Richmond; F Jay Garcia; Julia C Durante; Kathleen M Ulrich; Christine M Roberts; Christopher D Link; Walter F Stafford; Thomas M Laue; Robert Fairman
Journal:  Protein Sci       Date:  2015-12-21       Impact factor: 6.725

7.  Expression and purification of amyloid-beta peptides from Escherichia coli.

Authors:  Kanchan Garai; Scott L Crick; Sourajit M Mustafi; Carl Frieden
Journal:  Protein Expr Purif       Date:  2009-02-20       Impact factor: 1.650

8.  Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3.

Authors:  Rajakishore Mishra; Manoj K Barthwal; Gautam Sondarva; Basabi Rana; Lucas Wong; Malay Chatterjee; James R Woodgett; Ajay Rana
Journal:  J Biol Chem       Date:  2007-08-21       Impact factor: 5.157

9.  Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet.

Authors:  Lauren E Buchanan; Emily B Dunkelberger; Huong Q Tran; Pin-Nan Cheng; Chi-Cheng Chiu; Ping Cao; Daniel P Raleigh; Juan J de Pablo; James S Nowick; Martin T Zanni
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 10.  Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.

Authors:  Jing Liu; Bin Yang; Jun Ke; Wenjia Li; Wen-Chen Suen
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.